Target market. 1 billion people.
SAN DIEGO--(BUSINESS WIRE)-- A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conferenceindicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates.This press release features multimedia. View the full release here: The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacted population significantly larger than previously identified.
Ann: ResApp Announces SleepCheck, a Sleep Apnoea Screening App, page-40
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #